ResearchMoz

Pharmaceuticals Monthly Deals Analysis: October 2013 - Partnerships, Licensing, Investments and M&A Trends

GlobalData
Published Date » 2013-11-30
No. Of Pages » 107
   
 GlobalData's Pharmaceuticals Monthly Deals Analysis: October 2013 Partnerships, Licensing, Investments and M&A Trends report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in October 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals...
Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, October 2013 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, October 2013 14
2.2.1 McKesson to Acquire Celesio for US$8.3 Billion 14
2.2.2 Bristol-Myers Squibb Completes Public Offering of Notes for US$1.5 Billion 16
2.2.3 Ventas Acquires Portfolio of Independent Living Communities from Holiday Retirement for US$790 Million 16
2.2.4 BioMarin Pharma Completes Public Offering of Notes for US$750 Million 16
2.2.5 Astellas Pharma Enters Into R&D Agreement with Mitokyne for Drug Discovery 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, October 2013 18
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, October 2013 19

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
3.1 Pharmaceuticals & Healthcare, Global, M&A, October 2013 20
3.1.1 Top M&A Deals in October 2013 21
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, May 2013 - October 2013 22
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, October 2013 23
3.2.1 Top Equity Offering Deals in October 2013 24
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, May 2013 - October 2013 25
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, October 2013 27
3.3.1 Top PE/VC Deals in October 2013 28
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, October 2013 29
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, October 2013 31
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, May 2013-October 2013 33
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2013-October 2013 34

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2013 35
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2013 35
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, May 2013 - October 2013 37
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 39
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, October 2013 41
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 42
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, May 2013 - October 2013 44
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), May 2013 - October 2013 45
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 47

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2013 49
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2013 49
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2013 51
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, October 2013 53
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, October 2013 53
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, October 2013 54
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), May 2013 - October 2013 55
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), May 2013 - October 2013 57
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), May 2013 - October 2013 59
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), May 2013 - October 2013 61

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 63
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, October 2013 63
6.1.1 Oncology - Deals of the Month 65
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, October 2013 67
6.2.1 Central Nervous System - Deals of the Month 69
6.3 Pharmaceuticals & Healthcare, Global, Immunology Deals, October 2013 70
6.3.1 Immunology - Dealsof the Month 72
6.4 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, October 2013 73
6.4.1 Infectious Diseases - Deals of the Month 75
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, October 2013 76
6.5.1 Metabolic Disorders - Deal of the Month 78
6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, October 2013 81
6.6.1 Cardiovascular - Deal of the Month 82
6.7 Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals, October 2013 84
6.7.1 Hematological Disorders - Deal of the Month 85

7 Deal Summary by Geography 87
7.1 Pharmaceuticals & Healthcare, North America Deals, October 2013 87
7.1.1 North America - Deals of the Month 89
7.2 Pharmaceuticals & Healthcare, Europe, Deals, October 2013 91
7.2.1 Europe - Deals of the Month 92
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, October 2013 94
7.3.1 Asia-Pacific - Deals of the Month 96
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, October 2013 97
7.4.1 Rest of the World - Deals of the Month 99

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 100
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, May 2013 - October 2013 100
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, May 2013 - October 2013 102

9 Further Information 104
9.1 Methodology 104
9.2 About GlobalData 105
9.3 Disclosure information 106
9.4 Disclaimer 106

List of Tables


Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, October 2013 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), October 2013 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 21
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, October 2013 21
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 22
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 24
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, October 2013 24
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 26
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 28
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, October 2013 28
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, May 2013 - October 2013 30
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), October 2013 32
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 33
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2013 - October 2013 34
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 36
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 38
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 40
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), October 2013 41
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 43
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 46
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), May 2013 - October 2013 48
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 50
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 52
Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, October 2013 53
Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, October 2013 53
Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, October 2013 54
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 56
Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), October 2013 58
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 60
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 62
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 64
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 68
Table 34: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 71
Table 35: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 74
Table 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 77
Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 82
Table 38: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 85
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 88
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 92
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 95
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 98
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 101
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 103

List of Figures


Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), October 2013 18
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), October 2013 19
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 20
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 22
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 23
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 25
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 27
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 29
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), October 2013 31
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), October 2013 32
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 33
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 35
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 37
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 39
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 42
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 44
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 45
Figure 19:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 47
Figure 20:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 49
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 51
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 55
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 57
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, May 2013 - October 2013 59
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), May 2013 - October 2013 60
Figure 26:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 61
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 63
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 67
Figure 29: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 70
Figure 30: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 73
Figure 31: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 76
Figure 32: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 81
Figure 33: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 84
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 87
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 91
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 94
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 97
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 100
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 102

Upcoming Reports:

Fluid Management And Visualization Systems Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
The market for fluid management and visualization systems consists of devices such as dialyzers, insufflators, suction and evacuation devices, fluid warming systems, tubing sets, catheters, suction canisters, camera heads, video processors and endoscopic cameras. These devices are widely used in endoscopic procedures to treat people with kidney failure, obesity, cardiovascular disease, orthopedic conditions, neurological disease, cancer, gastrointestinal and respiratory diseases. The fluid management and visualization systems market has been broadly segmented into fluid management devices...
Next Generation Memory Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
The fast growth shown by consumer electronics segment and technological and design changes made therein; the demand for faster, smaller and low cost memory devices (RAM – Random Access Memory)) has gone up. Leading global electronics and IT giants such as Samsung, IBM, HP, Toshiba, and so on, are continuously investing more on research work in the field of next generation memory technologies. Though in near future the existing memories technologies are still expected to dominate the market, the need of newer technologies in becoming inevitable, and many new projects are in...
Polymer Microinjection Molding Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Microinjection molding is a process in which high pressure machines are required for molding tools and parts in to miniature components. The machines used in the process should be capable of high pressures and speed, steady melt temperature, precise shot control and ultra fine controls. Materials used in micro molding are liquid crystal polymers (LCP), polyester, polycarbonate and acetal among others. Microinjection molding is used in various applications such as medical, electronics, automotive components, watches, telecommunication, micromechanics, optics and sensors among others. The...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Typhoon Rammasun hits Yangjiang, Guangdong province
Jul 22, 2014  
The largest typhoon to hit the southern part of China in forty years has resulted in death of 17 people after wreaking havoc on Philippines. The typhoon Rammasun has resulted in deaths of eight people on the island of Hainan. Many people are recorded missing and nine of these from the Guangxi region. This typhoon caused landfall on Friday, and was reported with winds exceeding 200...
Allergan to Slash 1,500 Jobs Amid Fighting Valeant Bid
Jul 22, 2014  
Allergan, best known as the maker of Botox, has announced plans to slash 13% of its workforce, which means that 1,500 employees will be facing the axe. Allergan said that the massive layoffs are in an effort to make the company more productive and efficient. The company, based in Irvine, California, said Monday that nearly 250 vacant positions will be eliminated as part of this...
Netflix Surpasses Projected Earnings in Second Quarter of 2014 with Double the Profits
Jul 22, 2014  
Netflix, the internet video services provider, has reported that its earnings in the second quarter more than doubled. The company attributed this spike in earnings to the success of new episodes from one of its highly successful series. This has helped Netflix’s customer base to reach higher than 50 million worldwide – highest ever in the company’s history. The...
Oil deal between China and Venezuela
Jul 22, 2014  
Venezuela and China have come together and signed mineral and oil deals. Some very significant deals with Brazil and Argentina have already been signed by Mr. Xi Jinping, the Chinese president. The next country, with which he will sign a deal with, is Cuba.  Mr. Xi has agreed to pay a currency swap valued at USD 11 billion to Argentina and this will fulfill the requirement of funds...
Malaysia Airlines most Likely to be Delisted after Ukraine Disaster
Jul 22, 2014  
With two major disasters hitting Malaysia Airlines in four months, it could possibly be heading towards a delisting. The two options staring Malaysian Air are either going private with Khazanah Nasional Bhd taking it under its wings, or declaring bankruptcy. Both options will eventually lead to the airlines being delisted. If Malaysian Air decides to opt for bankruptcy, in terms of assets, it...